NEW YORK — Del Laboratories managed to increase second-quarter profits despite charges associated with shifts in its manufacturing.

For the three months ended June 30, net income grew 7.6 percent to $4.9 million, or 52 cents a diluted share, from $4.6 million, or 48 cents, in the year-ago period. Excluding a $1.2 million after-tax charge to cover severance for those affected by the shift of manufacturing to Rocky Point, N.C., from Farmingdale, N.Y., income would have risen 32.8 percent to $6.1 million. Net sales picked up 5.1 percent to $98 million from $93.3 million.

“The move to North Carolina will consolidate our principal manufacturing operations with our major distribution facility and result in improved operating efficiencies and reduced manufacturing expenses,” said Dan Wassong, chairman, president and chief executive, in a statement, adding that the firm had extended the lease for its Uniondale, N.Y., headquarters through 2014 and added 41,000 square feet to its space there to accommodate administrative personnel who were previously based in Farmingdale.

“The consolidation of our corporate and administrative offices will also improve our administrative efficiencies,” Wassong said.

In the six months, net income dropped 2.9 percent to $9.3 million, or 97 cents a diluted share, from $9.5 million, or $1.02. However, excluding this year’s severance charges and a $1.5 million after-tax gain from a land sale, earnings would have grown 29 percent to $10.4 million from $8.1 million. The firm, whose Sally Hansen brand has a leading portion of the mass-market nail care category with a 26 percent share, saw sales grow 10.5 percent in the half to $191.3 million from $173.2 million.

To access this article, click here to subscribe or to log in.

load comments
blog comments powered by Disqus